# Triazolam
*Source: https://go.drugbank.com/drugs/DB00897*

## Overview

### Description

This compound belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring.

### Background

Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.

### Indication

For the short-term treatment of insomnia.

### Pharmacodynamics

A short-acting benzodiazepine used as a hypnotic agent in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. Triazolam has a shorter half-life than chlordiazepoxide, flurazepam, and prazepam and does not generate active metabolites.

### Mechanism of Action

GABA(A) Receptor
Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site
Ligand

### Absorption

Bioavailability is 44% (oral) and 53% (sublingual).

### Metabolism

Hepatic. Small amounts of unmetabolized triazolam appear in the urine.
Hover over products below to view reaction partners
Triazolam
4-hydroxytriazolam
1'-hydroxytriazolam

### Half-life

1.5-5.5 hours

### Toxicity

Symptoms of overdose include drowsiness, slurred speech, motor inco-ordination, coma, and respiratory depression.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Triazolam is combined with 1,2-Benzodiazepine.
Abacavir
Triazolam may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir
The serum concentration of Triazolam can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Triazolam can be increased when combined with Abatacept.
Acalabrutinib
The metabolism of Triazolam can be decreased when combined with Acalabrutinib.

### Food Interactions

Avoid alcohol. Ingesting alcohol may increase the risk of complex behaviors like sleep-driving, which the patient does not remember.
Avoid grapefruit products. Grapefruit may reduce the CYP3A4 metabolism of triazolam, which increases the serum concentration of triazolam.

## Chemical Information

**DrugBank ID:** DB00897

**Synonyms:** Triazolam
Triazolamum

**Chemical Formula:** C
17
H
12
Cl
2
N
4

**SMILES:** CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C3=C(C=CC(Cl)=C3)N12

**Weight:** Average: 343.21
Monoisotopic: 342.043901818

**IUPAC Name:** 12-chloro-9-(2-chlorophenyl)-3-methyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

1

### Phase 0

0

### Phase 1

7

### Phase 2

2

### Phase 3

2

### Phase 4

1

### Therapeutic Categories

Benzodiazepines and benzodiazepine
derivatives

### Summary

Triazolam
is a benzodiazepine used for short term treatment of insomnia.

### Brand Names

Halcion

### Generic Name

Triazolam

### DrugBank Accession Number

DB00897

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Triazolam (DB00897)
×
Close

### External IDs

DEA No. 2887
N05CD05
U 33030

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Insomnia
••••••••••••
Create Account
Create Account

### Associated Therapies

Sedation

### Mechanism of action

Benzodiazepines bind nonspecifically to bezodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABA
A
) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Target
Actions
Organism
A
GABA(A) Receptor
positive allosteric modulator
Humans
A
GABA(A) Receptor Benzodiazepine Binding Site
ligand
Humans
U
Translocator protein
modulator
Humans

### Route of elimination

Triazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine. Only small amounts of unmetabolized triazolam appear in the urine. The two primary metabolites accounted for 79.9% of urinary excretion.

### Product Images

Previous
Next

### International/Other Brands

Apo-Triazo (Apotex)
/
Arring (YungShin)
/
Asasion (Choseido Pharmaceutical Co., Ltd)
/
Ascomarna (Nisshin Seiyaku K.K)
/
Songar (Valeas S.p.A.)

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Halcion
Tablet
0.125 mg
Oral
Pfizer Italia S.R.L.
1980-12-31
2006-08-02
Canada
Halcion
Tablet
.125 mg/1
Oral
Pharmacia &amp; Upjohn Company LLC
2006-01-19
2006-01-19
US
Halcion
Tablet
0.25 mg
Oral
Pfizer Italia S.R.L.
1978-12-31
2007-05-29
Canada
Halcion
Tablet
0.25 mg/1
Oral
Physicians Total Care, Inc.
1982-11-15
2012-06-30
US
Halcion
Tablet
0.25 mg/1
Oral
Pharmacia &amp; Upjohn Company LLC
1982-11-15
Not applicable
US

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Alti-triazolam Tab 0.125mg
Tablet
.125 mg / tab
Oral
Altimed Pharma Inc.
1987-12-31
2001-09-05
Canada
Alti-triazolam Tab 0.25mg
Tablet
.25 mg / tab
Oral
Altimed Pharma Inc.
1987-12-31
2001-09-05
Canada
Mylan-triazolam
Tablet
0.125 mg
Oral
Mylan Pharmaceuticals Inc.
1992-12-31
2011-03-04
Canada
Mylan-triazolam
Tablet
0.25 mg
Oral
Mylan Pharmaceuticals Inc.
1992-12-31
2011-03-04
Canada
Novo-triolam Tab 0.125mg
Tablet
.125 mg
Oral
Novopharm Limited
1990-12-31
2005-08-10
Canada

### ATC Codes

N05CD05 — Triazolam
N05CD — Benzodiazepine derivatives
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Adjuvants, Anesthesia
Agents Causing Muscle Toxicity
Anti-Anxiety Agents
Benzazepines
Benzodiazepine hypnotics and sedatives
Benzodiazepines and benzodiazepine derivatives
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2C8 Inhibitors
Cytochrome P-450 CYP2C8 Inhibitors (strength unknown)
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 CYP3A5 Substrates
Cytochrome P-450 CYP3A7 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Drugs that are Mainly Renally Excreted
GABA Agents
GABA Modulators
Heterocyclic Compounds, Fused-Ring
Hypnotics and Sedatives
Nervous System
Neurotransmitter Agents
Psycholeptics
Psychotropic Drugs
Tranquilizing Agents
Triazolobenzodiazepines

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 1,2,4-triazolo[4,3-a][1,4]benzodiazepines. These are aromatic compounds containing a 1,4-benzodiazepine fused to and sharing a nitrogen atom with a 1,2,4-triazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,2,4-triazolo[4,3-a][1,4]benzodiazepines
Alternative Parents
Chlorobenzenes
/
Aryl chlorides
/
Triazoles
/
Heteroaromatic compounds
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Hydrocarbon derivatives
Substituents
1,2,4-triazole
/
1,2,4-triazolo[4,3-a][1,4]benzodiazepine
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Azole
/
Benzenoid
/
Chlorobenzene
/
Halobenzene
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
triazolobenzodiazepine (
CHEBI:9674
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Benzodiazepines

### Sub Class

1,4-benzodiazepines

### Direct Parent

1,2,4-triazolo[4,3-a][1,4]benzodiazepines

### Alternative Parents

Chlorobenzenes
/
Aryl chlorides
/
Triazoles
/
Heteroaromatic compounds
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organochlorides
/
Hydrocarbon derivatives

### Substituents

1,2,4-triazole
/
1,2,4-triazolo[4,3-a][1,4]benzodiazepine
/
Aromatic heteropolycyclic compound
/
Aryl chloride
/
Aryl halide
/
Azacycle
/
Azole
/
Benzenoid
/
Chlorobenzene
/
Halobenzene

### Molecular Framework

Aromatic heteropolycyclic compounds

### External Descriptors

triazolobenzodiazepine (
CHEBI:9674
)

### Affected organisms

Humans and other mammals

### UNII

1HM943223R

### CAS number

28911-01-5

### InChI Key

JOFWLTCLBGQGBO-UHFFFAOYSA-N

### InChI

InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

### General References

Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [
Article
]
Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [
Article
]
Noguchi H, Kitazumi K, Mori M, Shiba T: Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats. J Pharmacol Sci. 2004 Mar;94(3):246-51. [
Article
]
Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [
Article
]
Veje JO, Andersen K, Gjesing S, Kielgast H: [Prescription of tranquilizers and hypnotics in the municipality of Holbaek]. Ugeskr Laeger. 1989 Aug 21;151(34):2134-6. [
Article
]

### External Links

Human Metabolome Database
HMDB0015034
KEGG Drug
D00387
PubChem Compound
5556
PubChem Substance
46509147
ChemSpider
5355
BindingDB
50001765
RxNav
10767
ChEBI
9674
ChEMBL
CHEMBL646
ZINC
ZINC000000002212
Therapeutic Targets Database
DAP000244
PharmGKB
PA451753
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Triazolam

### Human Metabolome Database

HMDB0015034

### KEGG Drug

D00387

### PubChem Compound

5556

### PubChem Substance

46509147

### ChemSpider

5355

### BindingDB

50001765

### RxNav

10767

### ChEBI

9674

### ChEMBL

CHEMBL646

### ZINC

ZINC000000002212

### Therapeutic Targets Database

DAP000244

### PharmGKB

PA451753

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### PDRhealth

PDRhealth Drug Page

### Wikipedia

Triazolam

### MSDS

Download
(5.44 KB)

### Manufacturers

Pharmacia and upjohn co
Alphapharm party ltd
Roxane laboratories inc
Watson laboratories inc

### Packagers

Alphapharm Party Ltd.
A-S Medication Solutions LLC
Bryant Ranch Prepack
Corepharma LLC
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Genpharm LP
Greenstone LLC
H.J. Harkins Co. Inc.
Keltman Pharmaceuticals Inc.
Mylan
Nucare Pharmaceuticals Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
PD-Rx Pharmaceuticals Inc.
Pfizer Inc.
Pharmacia Inc.
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Rebel Distributors Corp.
Roxane Labs
Southwood Pharmaceuticals
St Mary's Medical Park Pharmacy

### Dosage Forms

Form
Route
Strength
Tablet
Oral
.125 mg / tab
Tablet
Oral
.25 mg / tab
Tablet
Oral
.125 mg/1
Tablet
Oral
0.5 MG
Tablet
Oral
125 MICROGRAMMI
Tablet
Oral
250 MICROGRAMMI
Tablet
Oral
Tablet
Oral
0.125 mg
Tablet
Oral
.125 mg
Tablet
Oral
.25 mg
Capsule
Oral
0.25 MG
Capsule
Oral
0125 MG
Solution / drops
Oral
Tablet
Oral
0.1250 mg
Tablet
Oral
0.125 mg/1
Tablet
Oral
0.25 mg/1
Tablet
Oral
0.25 mg
Tablet
Oral
0125 MG

### Prices

Unit description
Cost
Unit
Halcion 10 0.25 mg tablet Bottle
21.0USD
bottle
Triazolam 10 0.125 mg tablet Bottle
6.33USD
bottle
Triazolam 10 0.25 mg tablet Bottle
6.0USD
bottle
Halcion 0.25 mg tablet
1.99USD
tablet
Halcion 0.125 mg tablet
1.37USD
tablet
Triazolam 0.25 mg tablet
0.67USD
tablet
Triazolam 0.125 mg tablet
0.65USD
tablet
Apo-Triazo 0.25 mg Tablet
0.22USD
tablet
Mylan-Triazolam 0.25 mg Tablet
0.22USD
tablet
Apo-Triazo 0.125 mg Tablet
0.12USD
tablet
Mylan-Triazolam 0.125 mg Tablet
0.12USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
233-235 °C
Not Available
water solubility
4.53 mg/L
Not Available
logP
2.42
BIOBYTE (1995)
logS
-4.08
ADME Research, USCD

### Predicted Properties

Property
Value
Source
Water Solubility
0.0183 mg/mL
ALOGPS
logP
2.94
ALOGPS
logP
3.63
Chemaxon
logS
-4.3
ALOGPS
pKa (Strongest Acidic)
17.98
Chemaxon
pKa (Strongest Basic)
4.26
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
43.07 Å
2
Chemaxon
Rotatable Bond Count
1
Chemaxon
Refractivity
103.68 m
3
·mol
-1
Chemaxon
Polarizability
34.19 Å
3
Chemaxon
Number of Rings
4
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
1.0
Blood Brain Barrier
+
0.9719
Caco-2 permeable
+
0.886
P-glycoprotein substrate
Non-substrate
0.5252
P-glycoprotein inhibitor I
Non-inhibitor
0.6788
P-glycoprotein inhibitor II
Inhibitor
0.8331
Renal organic cation transporter
Inhibitor
0.7628
CYP450 2C9 substrate
Non-substrate
0.7898
CYP450 2D6 substrate
Non-substrate
0.9208
CYP450 3A4 substrate
Substrate
0.751
CYP450 1A2 substrate
Inhibitor
0.8598
CYP450 2C9 inhibitor
Inhibitor
0.815
CYP450 2D6 inhibitor
Non-inhibitor
0.8226
CYP450 2C19 inhibitor
Inhibitor
0.7117
CYP450 3A4 inhibitor
Non-inhibitor
0.5596
CYP450 inhibitory promiscuity
High CYP Inhibitory Promiscuity
0.9088
Ames test
Non AMES toxic
0.9132
Carcinogenicity
Non-carcinogens
0.6714
Biodegradation
Not ready biodegradable
1.0
Rat acute toxicity
1.9971 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9638
hERG inhibition (predictor II)
Non-inhibitor
0.8806
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-0006-8089000000-80a2c04b55ba4ec57f7d
Mass Spectrum (Electron Ionization)
MS
splash10-0imr-4954000000-75bcea16a1182103168f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-439a372277eb9d7b84c5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-9a1a20ce1a0982eb608a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-ba834846753af69ac024
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-0006-0009000000-c2d9a1315e70661774c4
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-01ri-0096000000-e7da2771e1cfa7c211eb
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0f9x-3192000000-a6123eaa7899f05d0158
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
174.3785356
predicted
DarkChem Lite v0.1.0
[M-H]-
171.45076
predicted
DeepCCS 1.0 (2019)
[M+H]+
175.0905356
predicted
DarkChem Lite v0.1.0
[M+H]+
173.80876
predicted
DeepCCS 1.0 (2019)
[M+Na]+
174.9081356
predicted
DarkChem Lite v0.1.0
[M+Na]+
180.69753
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### Curator comments

This enzyme relationship is supported by 1 in vitro study available in the literature.

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of steroid hormones and vitamins (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:10681376, PubMed:11093772, PubMed:12865317, PubMed:2732228). Exhibits high catalytic activity for the formation of catechol estrogens from 17beta-estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2 (PubMed:12865317). Catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione (PubMed:2732228). Catalyzes the oxidative conversion of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine (PubMed:2732228)

### Specific Function

estrogen 16-alpha-hydroxylase activity

### Gene Name

CYP3A5

### Uniprot ID

P20815

### Uniprot Name

Cytochrome P450 3A5

### Molecular Weight

57108.065 Da

